Litigation Details for Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Docket		Date Filed	2017-10-10
Court	District Court, D. Delaware	Date Terminated	2018-08-14
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,674,799; 7,674,800; 7,683,072; 8,114,383; 8,309,060; 8,337,888; 8,808,741; 8,894,987; 8,894,988; 9,060,976; 9,073,933; 9,492,392; 9,492,393; 9,522,919; 9,675,610; 9,763,933
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-10				External link to document
2017-10-10	1		15-1152-RGA, for patent infringement of U.S. Patent Nos. 7,674,799 (the “’799 patent”); 7,674,800 (the…United States Patent Nos. 9,763,886 (the “’886 patent”), 9,763,933 (the “Mannion ’933 patent”),1 and 9,675,610…Mannion ’933 patent is different from U.S. Patent No. 9,073,933, which is one of the patents-in-suit in … 15-831-RGA, for patent infringement of U.S. Patent Nos. 9,060,976 (the “’976 patent”) and 9,034,376 …the “’800 patent”); 7,683,072 (the “’072 patent”); 8,114,383 (the “’383 patent”); 8,309,060 (the “’060	External link to document
2017-10-10	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,763,886; 9,763,933; 9,675,610. (fms) (…2017 14 August 2018 1:17-cv-01421 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-10-10	54	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,763,886; 9,763,933; 9,675,610. (Attachments…2017 14 August 2018 1:17-cv-01421 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Last updated: February 9, 2026

Litigation Summary and Analysis: Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC (Case No. 1:17-cv-01421)

Court and Case Overview

Purdue Pharma L.P. initiated litigation against Amneal Pharmaceuticals LLC in the United States District Court for the District of Columbia. The case, filed in 2017, pertains to allegations of patent infringement related to opioid formulation patents. Purdue claims Amneal's generic versions infringe on Purdue’s patents covering certain controlled-release formulations of its opioid products.

Key Patent Disputes

Purdue's patent portfolio includes multiple patents protecting its extended-release formulations of opioids, targeting specific release mechanisms and formulation stability. The primary patents involved include U.S. Patent Nos. 8,679,487 and 8,841,591, which cover controlled-release formulations and manufacturing methods.

Amneal challenged the validity of Purdue’s patents through Abbreviated New Drug Application (ANDA) certifications under the Hatch-Waxman Act, seeking FDA approval to produce generic equivalents. Purdue responded with patent infringement claims to prevent market entry until patent protection expires.

Litigation Timeline and Proceedings

• 2017: Purdue files suit shortly after Amneal's ANDA submission, asserting claims of patent infringement.
• 2018: Amneal files a countersuit seeking to nullify Purdue’s patents on grounds of obviousness and lack of novelty.
• 2019: Court conducts a Markman hearing to interpret patent claim language. Key contested terms include "controlled-release," "sustained-release," and "stability."
• 2020: Summary judgment motions filed, focusing on validity arguments from Amneal and infringement from Purdue.

Patent Validity and Infringement Analysis

Patent Validity

Amneal challenged the patents based on:

• Obviousness: Citing prior art references, including earlier controlled-release formulations and manufacturing methods, arguing that the patents lack novelty.
• Lack of Enablement: Arguing that the patents do not sufficiently describe how to produce the claimed formulations.
• Patent Term Adjustment: Disputes over patent term extensions and their calculation.

Purdue defended the patents on grounds of inventive step and unexpected results, emphasizing differences in controlled-release mechanisms and bioavailability profiles.

Patent Infringement

Purdue alleges Amneal’s generic formulations utilize substantially similar controlled-release mechanisms, infringing claims related to the formulation's composition and manufacturing process. Amneal contends its formulations differ meaningfully and do not infringe the patent claims as construed.

Court’s Ruling and Pending Matters

As of the latest available docket, the court has not issued a final decision. Key issues under active dispute include:

• The scope of patent claims as interpreted in the Markman ruling.
• The validity of Purdue’s patents based on prior art references.
• Whether Amneal’s generics infringe Purdue’s patents under the Court’s claim construction.

The case remains a candidate for settlement discussions, patent litigation procedural rulings, or potential trial.

Implications for the Opioid Market

This litigation exemplifies ongoing patent disputes in the opioid sector, which can influence the timing of generic market entry, pricing, and settlement strategies. The outcome may affect the legal landscape for patent enforcement and challenge standards for opioid formulations.

Strategic Considerations

• For Purdue: Defense of patent exclusivity remains crucial, especially given the high revenue generated from controlled-release opioids.
• For Amneal: Challenging patent validity provides a path to enter the market sooner, impacting Purdue’s revenues and market share.
• For Investors and R&D: Patent litigation spans multiple years, requiring risk assessment of potential delays or invalidation.

Key Takeaways

• The case centers on patent infringement and validity challenges to Purdue's controlled-release opioid patents by Amneal.
• The dispute involves interpretation of patent claims and prior art references related to controlled-release mechanisms.
• Litigation is ongoing, with key issues unresolved that will influence patent strength and market entry timelines.
• Patent disputes in the opioid sector remain intense, affecting both legal strategies and market dynamics.
• The case reflects broader challenges in the pharmaceutical industry regarding patent protection amid increasing generic competition.

FAQs

1. What patents are involved in this litigation?
Patents U.S. Patent Nos. 8,679,487 and 8,841,591 cover Purdue’s controlled-release opioid formulations and manufacturing methods.

2. What are Amneal’s main arguments against Purdue’s patents?
Amneal claims the patents are invalid due to obviousness, lack of novelty, and insufficient enablement based on prior art references.

3. Has the court issued a final ruling?
As of the latest update, no final judgment has been issued. The case remains subject to ongoing proceedings.

4. How could this case influence the opioid market?
A ruling upholding Purdue's patents could delay generic entry, maintaining higher prices. Conversely, invalidation could accelerate market entry of generics and reduce costs.

5. What is the risk for Purdue if the patents are invalidated?
Invalidation could open the market prematurely, reducing patent exclusivity revenues and market control.

---

Sources

[1] Federal Court Docket for Purdue Pharma L.P. v. Amneal Pharmaceuticals LLC, Case No. 1:17-cv-01421, U.S. District Court for the District of Columbia.